B· Original
After 40 years of little change, the AATD treatment market is being reshaped by gene and RNA editing and next-generation protein therapies

The alpha-1 antitrypsin deficiency (AATD) market, which has seen little change in treatment approaches for about 40 years, is emerging as a battleground for gene editing, RNA editing and next-generation protein replacement therapies.
Beam Therapeutics is viewed as having the leading program, potentially eligible for a regulatory filing as early as 2028, while Prime Medicine, CRISPR Therapeutics, Tessera Therapeutics and China’s YolTech have joined the competition. Sanofi and Wave Life Sciences have also released clinical data on different treatment strategies, making the potential shift in the AATD treatment paradigm increasingly concrete.
AATD is a rare genetic disease in which mutations in the SERPINA1 gene prevent the body from producing sufficient normal alpha-1 antitrypsin protein.
Normal AAT protein is produced in the liver and then travels through the bloodstream to the lungs, where it protects lung tissue from inflammatory enzymes. In patients with severe AATD, however, abnormal Z-AAT protein can accumulate in the liver and cause liver damage, while low blood levels of AAT increase the risk of emphysema and COPD.

Why it is suitable for gene editing
• Many patients with severe disease have similar genetic causes, such as the PiZ mutation.
• The liver, where the disease-related protein is produced, is an organ to which in vivo gene-editing tools can currently be delivered relatively reliably.
• Correcting the mutation could increase production of normal AAT while reducing Z-AAT accumulation in the liver.
• The approach is more likely to involve a single standardized therapy rather than a personalized treatment for each patient.
02. A treatment paradigm shift taking shape after 40 years
For the past 40 years, the main treatment for AATD has been replacement therapy, in which AAT protein is isolated from donated plasma and administered by intravenous infusion each week. Existing replacement therapy temporarily supplements deficient AAT protein but requires lifelong repeated dosing and cannot remove the mutant Z-AAT that accumulates in the liver.
Recently, different next-generation approaches, ranging from long-acting protein replacement therapies to RNA and DNA editing, have entered clinical development simultaneously.

03. Market size and growth outlook
Market research firms define the overall treatment market and the existing replacement-therapy market differently, resulting in wide variations in estimates. Rather than relying on a single market-size figure, it is therefore necessary to examine each firm’s analytical scope and growth assumptions.

04. Competitive landscape for AATD therapies
Different technology platforms are competing in the AATD market, including in vivo gene editing, RNA editing, protein replacement therapy and RNAi. Each candidate is establishing a distinct position in terms of dosing convenience, durability of effect, the potential to treat the liver and lungs simultaneously, and safety.

05. Strategic analysis of key developers
Sanofi: advancing long-acting protein replacement therapy
Sanofi’s efdoralprin alfa is a recombinant AAT protein therapy designed to extend persistence in the body. Unlike existing plasma-derived therapies administered once a week, it is intended for dosing every 3 or 4 weeks.

Clinical significance
• It suggests that weekly intravenous infusions could potentially be extended to intervals of 3 to 4 weeks.
• Administration every 3 weeks was found to have the potential to maintain functional AAT within the normal range consistently.
• The strategy maintains the mechanism of action of existing replacement therapy while reducing the treatment burden for patients.
• Long-term clinical trials are needed to determine whether it actually slows deterioration in lung function and emphysema progression.
Wave: disease correction based on reversible RNA editing
Wave Life Sciences’ WVE-006 edits SERPINA1 RNA to induce production of normal M-AAT instead of mutant Z-AAT.

Technical advantages
• It is a reversible treatment strategy that does not permanently alter DNA.
• It may increase normal M-AAT while also reducing Z-AAT accumulation in the liver.
• It could be an alternative for patients concerned about permanent genetic modification.
• Monthly subcutaneous injections could offer greater dosing convenience than existing intravenous infusion therapy.
Development challenges
• Unlike Beam’s one-time gene-editing treatment, it requires repeated dosing.
• Its actual effects on lung function and liver disease have not yet been established.
• Because its clinical trial design differs from Beam’s, direct comparisons of efficacy are difficult.
Prime Medicine: PM647 gains development visibility after arbitration victory
Prime Medicine’s PM647 and Beam’s BEAM-302 both correct the PiZ mutation in SERPINA1, but they use different gene-editing technologies.

Arbitration outcome
• The arbitration tribunal determined that PM647 fell within Prime’s development field under the 2019 agreement.
• Prime was found not to have breached its agreement with Beam.
• Prime is not obligated to pay damages to Beam.
• Prime can continue the clinical development of PM647.
• Prime is targeting an IND or CTA submission in the third quarter of 2026 and the release of initial clinical data in 2027.
This decision was not the outcome of a patent lawsuit determining patent validity or infringement. It was a contractual arbitration decision recognizing Prime’s development rights for PM647 under the 2019 collaboration and licensing agreement. Beam said it disagreed with parts of the ruling and would continue defending its foundational patents and collaboration rights. As a result, the possibility remains that the matter could expand into a separate patent dispute.
06. Key timeline in the AATD treatment development race
● December 2016 Potential application of gene editing proposed
John Evans encountered David Liu’s base-editing technology at the Broad Institute and proposed its potential application to AATD.
● 2018 Beam Therapeutics launched
Beam began full-scale development of liver-targeted lipid nanoparticles and an in vivo base-editing system.
● 2019 Prime Medicine founded and agreement signed with Beam
Prime Medicine was launched based on prime-editing technology. Beam and Prime entered into a collaboration and licensing agreement distinguishing their development fields and technology-use rights.
● 2022 Prime’s undisclosed program and YolTech founded
Prime was reported to have begun developing an AATD program internally. Around the same time, researchers from Beam and Tessera participated in founding YolTech in China.
● June 2024 Beam doses first patient with BEAM-302
Beam began the first clinical dosing of BEAM-302 in patients with AATD.
● 2024 Sanofi secures next-generation protein therapy
Through its acquisition of Inhibrx, Sanofi secured the long-acting recombinant AAT therapy efdoralprin alfa. The transaction was valued at up to $2.2 billion.
● 2025 Public competition and rights disputes intensify
Prime and CRISPR Therapeutics disclosed their AATD programs. Beam initiated contractual arbitration against Prime, while Regeneron entered into a co-development agreement with Tessera.
● 2025 YolTech releases early clinical data
YolTech announced that it observed higher efficacy than Beam in 1 of the first 2 patients. However, this was not a head-to-head trial conducted under identical conditions with Beam.
● March 2026 YolTech receives FDA IND clearance
The FDA IND for initiating global phase 2/3 clinical trials of YOLT-202 was cleared.
● May 2026 Sanofi and Wave announce new clinical data
Sanofi released phase 2 results for efdoralprin alfa, while Wave presented clinical data on RNA editing with WVE-006 at the American Thoracic Society.
● June 2026 Serapha Bio launches
Serapha announced total investment commitments of $230 million and licensed YolTech’s AATD technology. It plans to use the Nasdaq ticker “AATD” after completion of the merger.
● July 2026 Prime prevails in arbitration with Beam
The arbitration tribunal determined that PM647 fell within Prime’s contractual development field. Beam said it would continue defending its patents and collaboration rights.
● Expected in 2028 Beam’s potential filing window
Beam is viewed as having the leading program, potentially eligible for a regulatory filing as early as 2028. However, the timeline may change depending on the results of clinical trials and discussions with regulators.
09. Geopolitical factor: BIOSECURE Act
The inclusion of provisions related to the BIOSECURE Act in the U.S. FY2026 National Defense Authorization Act in December 2025 increased regulatory uncertainty surrounding relationships between Chinese biotechnology companies and U.S. federal procurement and federal funding.
Transactions licensing Chinese technology, such as Serapha–YolTech, are not immediately prohibited. However, indirect regulatory risks could arise depending on the scope of future designations of biotechnology companies of concern and the structure of federal procurement, federal funding and manufacturing services.

10. Key implications from an investor perspective
① Premiums are forming around diseases with clear genetic causes and deliverability
• Diseases that combine a common mutation, a clear disease mechanism and an accessible organ are uncommon.
• Sanofi’s acquisition of up to $2.2 billion and the Regeneron–Tessera agreement show that a real premium is forming around such indications.
• The ability to identify rare diseases early that are suitable for next-generation gene and RNA editing technologies could determine investment outcomes.
② Technology leadership alone is unlikely to secure a long-term monopoly
• The Beam–Prime arbitration and YolTech’s rapid pursuit show that the rights structure for gene editing cannot be resolved through a single patent alone.
• Clinical data, delivery vehicles, manufacturing processes, freedom to operate and regulatory risks must be evaluated together.
• More important than an early technology advantage is how long a company can maintain an advantage in clinical data.
③ Target patient populations may become segmented according to treatment strategy

④ After approval, patient identification and reimbursement will be key commercialization variables
• Because AATD progresses slowly, demonstrating an actual effect on preventing disease worsening may take a long time.
• A substantial number of patients are estimated to be undiagnosed or misdiagnosed.
• Patient-identification infrastructure, including genetic testing, medical-record analysis and screening of patients with COPD, could determine the expansion of therapy sales.
• Reimbursement and country-specific cost-effectiveness assessments are also expected to be major commercialization hurdles.

Biobook Team
biobook@biobook.co.kr